Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 1;105(12):2868-2871.
doi: 10.3324/haematol.2019.230805.

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Andrew R Pettitt  1 , Richard Jackson  2 , Silvia Cicconi  2 , Fotis Polydoros  2 , Christina Yap  3 , James Dodd  2 , Matthew Bickerstaff  2 , Michael Stackpoole  2 , Umair T Khan  1 , Stacey Carruthers  2 , Melanie Oates  2 , Ke Lin  4 , Sarah E Coupland  4 , Geetha Menon  4 , Nagesh Kalakonda  4 , Helen McCarthy  5 , Adrian Bloor  6 , Anna Schuh  7 , Andrew Duncombe  8 , Claire Dearden  9 , Christopher Fegan  10 , Ben Kennedy  11 , Renata Walewska  5 , Scott Marshall  12 , Christopher P Fox  13 , Peter Hillmen  14
Affiliations

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial

Andrew R Pettitt et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier plots showing progression-free and overall survival for the different induction and post-induction treatments. (A) Progression-free survival of the alemtuzumab and ofatumumab cohorts from study registration; (B) overall survival of the alemtuzumab and ofatumumab cohorts from study registration; (C) progression-free survival of patients who were randomised to lenalidomide maintenance or no further treatment or received a hematopoietic stemcell transplant; (D) overall survival of patients who were randomised to lenalidomide maintenance or no further treatment or received a hematopoietic stemcell transplant.
See this image and copyright information in PMC

References

    1. Pettitt AR, Jackson R, Carruthers S, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol. 2012;30(14):1647-1655. - PubMed
    1. Stilgenbauer S, Cymbalista F, Leblond V, et al. Alemtuzumab combined with dexamethasone, followed by alemtuzumab maintenance or allo-SCT in “ultra High-risk” CLL: final results from the CLL2O phase II study. Blood. 2014;124(21):1991-1991.
    1. Oscier D, Dearden C, Eren E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541-564. - PubMed
    1. Arumainathan A, Kalakonda N, Pettitt AR. Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. Eur J Haematol. 2011; 87(4):372-375. - PubMed
    1. Riches JC, Gribben JG. Mechanistic and clinical apects of lenalidomide treatment for chronic lymphocytic leukemia. Curr Cancer Drug Targets. 2016;16(8):689-700. - PubMed

Publication types

MeSH terms